Alantra Partners Sa · BME:ALNT
Alantra Partners Sa — H1 2020 Earnings Presentation
21 slides from Alantra Partners Sa's earnings presentation, Jul 29, 2020
Slide 1: 2020 H1 Results Presentation
2020 H1 Results Presentation 29th July 2020
Slide 2: I. 2020 H1 highlights
I. 2020 H1 highlights Net revenues reached €80.6 Mn (-1.4% vs 2019 H1) ▪ Net revenues from investment banking and credit portfolio advisory increased by 17.7% and 2.2% respectively ▪ In Alternative Asset Management, revenues from management fees reached €11.8 Mn (-6.0%). The absence of performance f
Slide 3: II. Our response to COVID-19 and how it will impact our business
II. Our response to COVID-19 and how it will impact our business 1 Sound financial position and P&L structure should mitigate the overall impact on the Group ▪ We have a sound financial position with a high solvency ratio, substantially exceeding our capital requirements: over €160 Mn of cash, cash
Slide 4: III. Key highlights of the business activity YTD
III. Key highlights of the business activity YTD Investment Banking Credit Portfolio Advisory Asset Management Direct investments 60 closed deals 2020YTD1,2 Highly international activity ▪ Relevant activity and new closings despite the (+11% vs. last year) market turmoil caused by COVID-19 ▪ Closed
Slide 5: IV. Net revenues reached €80.6 Mn (-1.4% vs. 2019 H1)
IV. Net revenues reached €80.6 Mn (-1.4% vs. 2019 H1) Net revenues for 2020 H1 Net revenues by division for 2020 H1 Breakdown of AM revenues by type (€’000) (€’000) (€’000) 81,764 Total AM 80,633 485 (45.7%) 637 21,703 81,764 80,633 11,784 2,975 Alantra WM 21,703 fees n.a. 12,713 Performance Total C
Slide 6: V. Operating expenses amounted to €66.4 Mn (-11.8% vs. 2019 H1)
V. Operating expenses amounted to €66.4 Mn (-11.8% vs. 2019 H1) Total operating expenses 2020 H1 (€’000) Breakdown of personnel expenses in 2020 H1 (€’000) 75,341 6,843 66,416 Amort. & imp. 2,917 15,073 (57.4%) 53,425 51,860 11,639 Other opex 22,177 Variable 17,144 (22.8%) (22.7%) 53,425 51,860 Pers
Slide 7: VI. Net Profit attributable to the parent of €11.1 Mn (-48.7% vs. 2019 H1)
VI. Net Profit attributable to the parent of €11.1 Mn (-48.7% vs. 2019 H1) 2020 H1 net profit breakdown1 Evolution of the net profit attributable to the parent (€’000) (€’000) 25 , 00 (901) 21,705 10,870 1,170 11,139 20 , 00 15 , 00 12,126 11,139 10,870 10 , 00 8,939 5,00 641 1,170 (901) - Net profi
Slide 8: VII. Strong Balance sheet as of 30th June 2020
VII. Strong Balance sheet as of 30th June 2020 €’000 122,419 2,397 248,659 379,628 88,125 379,628 44,311 39,672 247,192 84,171 48,701 130,969 €37,200 – Portfolio €78,985 – Monetary fund 82,268 €5,131 – Other non current financial assets €1,103 – Other financial assets Cash and cash Other current Tot
Slide 9: VIII. Strong shareholder remuneration policy
VIII. Strong shareholder remuneration policy ▪ An interim dividend on 2019 profit of 0.60 euros per share was paid on December 19th 2019 ▪ The Board of Director’s has approved the 2019 annual accounts and decided to propose to the Annual Shareholder’s Meeting, that will take place in October, the pa
Slide 10: IX. Investment Banking activity
IX. Investment Banking activity 2020 2020 60 closed deals 2020YTD1 (+11% vs. last year) According to Mergermarket, Alantra ranks in 2020 H1: ▪ Amongst top 5 independent advisors in Europe2 ▪ #2 independent advisor on global buyouts2 Alantra advised Saber Alantra advised Bridgepoint on Interactive on
Slide 11: X. Credit Portfolio Advisory activity
X. Credit Portfolio Advisory activity Strengthening of the European team and opening Highly international activity of new offices in China and Brazil ▪ Closed deals in 5 different countries (Spain, Portugal, UK, ▪ 5 senior hires in UK, Greece, Portugal and Latam Greece and Italy) ▪ Opening of new of
Slide 12: XI. Asset Management activity
XI. Asset Management activity 1 Direct Investments: relevant activity and new closings despite the market turmoil caused by COVID-19 Private ▪ Closing of the acquisition and integration of the three Spain-headquartered genetic diagnostic companies Imegen, Genycell Biotech Equity and Health in Code,
Slide 13: Annex
Annex 13 ALANTRA
Slide 14: I. Consolidated income statement for 2020 H1
Annex I. Consolidated income statement for 2020 H1 30/06/2020 30/06/2019 % 55,499 47,134 17.7% 12,713 12,442 2.2% 11,784 21,703 (45.7%) 11,784 12,530 (6.0%) - 6,198 (100.0%) Wealth Management Fees - 2,975 (100.0%) 637 485 31.3% 80,633 81,764 (1.4%) (50.0%) (51,860) (53,425) (2.9%) (34,716) (31,248)
Slide 15: II. Consolidated balance sheet as of 30th June 2020
Annex II. Consolidated balance sheet as of 30th June 2020 ASSETS LIABILITIES AND EQUITY 15
Slide 16: III. Consolidated 2020 H1 income statement by segment
Annex III. Consolidated 2020 H1 income statement by segment Consolidation Total Total Investment Banking Credit portfolio advisory Asset Management Structure Portfolio Rest adjustments Group Group 30/06/2020 30/06/2019 30/06/2020 30/06/2019 30/06/2020 30/06/2019 30/06/2020 30/06/2019 30/06/2020 30/0
Slide 17: IV. Glossary (i)
Annex 4. Annex IV. Glossary (i) Identified business segments “Business Segments” refer to each operating segment or component identified and classified as such by Alantra that (a) engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relat
Slide 18: IV. Glossary (ii)
Annex 4. Annex IV. Glossary (ii) “Fee Business” is defined as the group or aggregate of the Investment Banking, Credit Portfolio Advisory, Asset Management and Structure segments which, as a whole, are referred to as the service provision businesses, whether those services be financial advisory or m
Slide 19: IV. Glossary (iii)
Annex 4. Annex IV. Glossary (iii) “Recurring Net Profit”. The profit derived from the Group's recurring or ordinary activities, i.e., that generated by the Investment Banking, Credit Portfolio Advisory, Asset Management and Portfolio segments. ▪ Recurring Net Profit is the sum of Fee Business Net Pr
Slide 20: Disclaimer
Disclaimer Alantra Partners, S.A. publishes this presentation solely and exclusively for information purposes. This presentation does not constitute an offer to subscribe, buy or sell securities issued by Alantra Partners, S.A., or any other securities in any jurisdiction. Any information and foreca
Slide 21: Contact
Contact Philipp Krohn Investor Relations Tel.: +34 917 458 484 investors@alantra.com I www.alantra.com 21